Advertisement

Topics

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 16/12/2016, Revision: 3, Status: Authorised

11:11 EDT 12 Jul 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 16/12/2016, Revision: 3, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 16/12/2016, Revision: 3, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine / tenofovir disoproxil, HIV Infections, Date of authorisation: 16/12/2016, Revision: 3, Status: Authorised"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...